Matches in SemOpenAlex for { <https://semopenalex.org/work/W1917493316> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W1917493316 endingPage "908" @default.
- W1917493316 startingPage "S" @default.
- W1917493316 abstract "Introduction IL28B polymorphisms are linked to differences in SVR rates in HCV treatment-naOve patients treated with pegylated interferon (P) and ribavirin (R). REALIZE is a Phase 3 study that compared the efficacy, safety and tolerability of telaprevir (T), with or without a Lead-in (LI), in combination with PR against PR alone in prior treatment-failure patients including relapsers, partial responders and null responders (NR). Both T/PR arms were superior to control in all three patient categories. The relationship between IL28B genotype and SVR was investigated retrospectively. Method 527/662 (80%) patients enrolled in REALIZE consented to genetic testing. This represented 72%, 76% and 98% of the total relapsers, partial responders, and NR, respectively. Genotype rs12979860 was determined using a TaqMan allelic discrimination assay validated against Sanger sequencing on 50 independent samples. This was a retrospective study based on patients who consented to genetic testing prior to the discovery of IL28B, thus, sample size was not based on formal statistical considerations. Results Overall, 94% were Caucasian and 4% were Black. 18% of patients were IL28B CC, 61% CT and 21% TT. By prior response category, the highest proportion of IL28B TT patients was among prior NR (28%) while the highest frequency of CC patients occurred among prior relapsers (27%). The observed IL28B genotype frequencies indicate that the population was not in Hardy–Weinberg equilibrium (χ 2 =28, p Conclusion Differences in SVR rates among IL28B CC, CT and TT patients were only evident when the three patient subpopulations were pooled, however, SVR among CT and TT patients were still high. In this retrospective analysis, IL28B genotype did not contribute to outcome prediction in prior treatment-experienced patients treated with a telaprevir-based regimen and thus, may be of limited utility in this setting." @default.
- W1917493316 created "2016-06-24" @default.
- W1917493316 creator A5007518376 @default.
- W1917493316 creator A5016261953 @default.
- W1917493316 creator A5025261212 @default.
- W1917493316 creator A5026795331 @default.
- W1917493316 creator A5034390644 @default.
- W1917493316 creator A5044506772 @default.
- W1917493316 creator A5045504446 @default.
- W1917493316 creator A5048949272 @default.
- W1917493316 creator A5058911085 @default.
- W1917493316 creator A5060845872 @default.
- W1917493316 creator A5066724683 @default.
- W1917493316 creator A5071679284 @default.
- W1917493316 creator A5073741147 @default.
- W1917493316 creator A5075322332 @default.
- W1917493316 creator A5076282431 @default.
- W1917493316 creator A5078642431 @default.
- W1917493316 creator A5080386622 @default.
- W1917493316 date "2011-05-01" @default.
- W1917493316 modified "2023-09-25" @default.
- W1917493316 title "Similar SVR Rates in IL28B CC, CT or TT Prior Relapser, Partial- or Null-Responder Patients Treated With Telaprevir/Peginterferon/Ribavirin: Retrospective Analysis of the Realize Study" @default.
- W1917493316 doi "https://doi.org/10.1016/s0016-5085(11)63767-0" @default.
- W1917493316 hasPublicationYear "2011" @default.
- W1917493316 type Work @default.
- W1917493316 sameAs 1917493316 @default.
- W1917493316 citedByCount "9" @default.
- W1917493316 countsByYear W19174933162012 @default.
- W1917493316 countsByYear W19174933162013 @default.
- W1917493316 countsByYear W19174933162014 @default.
- W1917493316 crossrefType "journal-article" @default.
- W1917493316 hasAuthorship W1917493316A5007518376 @default.
- W1917493316 hasAuthorship W1917493316A5016261953 @default.
- W1917493316 hasAuthorship W1917493316A5025261212 @default.
- W1917493316 hasAuthorship W1917493316A5026795331 @default.
- W1917493316 hasAuthorship W1917493316A5034390644 @default.
- W1917493316 hasAuthorship W1917493316A5044506772 @default.
- W1917493316 hasAuthorship W1917493316A5045504446 @default.
- W1917493316 hasAuthorship W1917493316A5048949272 @default.
- W1917493316 hasAuthorship W1917493316A5058911085 @default.
- W1917493316 hasAuthorship W1917493316A5060845872 @default.
- W1917493316 hasAuthorship W1917493316A5066724683 @default.
- W1917493316 hasAuthorship W1917493316A5071679284 @default.
- W1917493316 hasAuthorship W1917493316A5073741147 @default.
- W1917493316 hasAuthorship W1917493316A5075322332 @default.
- W1917493316 hasAuthorship W1917493316A5076282431 @default.
- W1917493316 hasAuthorship W1917493316A5078642431 @default.
- W1917493316 hasAuthorship W1917493316A5080386622 @default.
- W1917493316 hasBestOaLocation W19174933161 @default.
- W1917493316 hasConcept C124101348 @default.
- W1917493316 hasConcept C126322002 @default.
- W1917493316 hasConcept C159047783 @default.
- W1917493316 hasConcept C203763787 @default.
- W1917493316 hasConcept C2522874641 @default.
- W1917493316 hasConcept C2778159067 @default.
- W1917493316 hasConcept C2780040827 @default.
- W1917493316 hasConcept C3020491458 @default.
- W1917493316 hasConcept C41008148 @default.
- W1917493316 hasConcept C71924100 @default.
- W1917493316 hasConcept C90924648 @default.
- W1917493316 hasConceptScore W1917493316C124101348 @default.
- W1917493316 hasConceptScore W1917493316C126322002 @default.
- W1917493316 hasConceptScore W1917493316C159047783 @default.
- W1917493316 hasConceptScore W1917493316C203763787 @default.
- W1917493316 hasConceptScore W1917493316C2522874641 @default.
- W1917493316 hasConceptScore W1917493316C2778159067 @default.
- W1917493316 hasConceptScore W1917493316C2780040827 @default.
- W1917493316 hasConceptScore W1917493316C3020491458 @default.
- W1917493316 hasConceptScore W1917493316C41008148 @default.
- W1917493316 hasConceptScore W1917493316C71924100 @default.
- W1917493316 hasConceptScore W1917493316C90924648 @default.
- W1917493316 hasIssue "5" @default.
- W1917493316 hasLocation W19174933161 @default.
- W1917493316 hasOpenAccess W1917493316 @default.
- W1917493316 hasPrimaryLocation W19174933161 @default.
- W1917493316 hasRelatedWork W1558399493 @default.
- W1917493316 hasRelatedWork W1917493316 @default.
- W1917493316 hasRelatedWork W1992249139 @default.
- W1917493316 hasRelatedWork W2070288517 @default.
- W1917493316 hasRelatedWork W2111335048 @default.
- W1917493316 hasRelatedWork W2126620144 @default.
- W1917493316 hasRelatedWork W2130138040 @default.
- W1917493316 hasRelatedWork W2331223604 @default.
- W1917493316 hasRelatedWork W4236946076 @default.
- W1917493316 hasRelatedWork W4240381849 @default.
- W1917493316 hasVolume "140" @default.
- W1917493316 isParatext "false" @default.
- W1917493316 isRetracted "false" @default.
- W1917493316 magId "1917493316" @default.
- W1917493316 workType "article" @default.